← Back to Search

Monoclonal Antibodies

Bevacizumab + Chemoimmunotherapy + Atezolizumab for Small Cell Lung Cancer with Liver Metastases(BELIEVE Trial)

Phase 2
Waitlist Available
Led By Kamya Sankar, MD
Research Sponsored by Kamya Sankar
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group staging system), and radiographic confirmation of LM at diagnosis.
Presence of measurable disease outside the CNS per RECIST v1.1.
Must not have
Screening 3 weeks
Treatment Varies
Follow Upfrom time of first dose until death from any cause, assessed up to approximately 48 months
Awards & highlights
No Placebo-Only Group

BELIEVE Trial Summary

This trial aims to find out if adding bevacizumab to atezolizumab and chemotherapy can help patients with ES-SCLC and liver metastases live longer without cancer progression.

Eligible Conditions
  • Small Cell Lung Cancer
  • Liver Metastases

BELIEVE Trial Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have been diagnosed with small cell lung cancer that has spread to your brain, confirmed by medical tests.
You have visible signs of disease in your body that can be measured according to a specific standard.
You have never had bleeding in your brain or spinal cord.
You previously had a specific type of lung cancer with a certain gene mutation, and it has now transformed into a different type that has spread to your liver. You have not received chemotherapy or immunotherapy for this type of cancer before.
You have a medical condition that can be measured using a standard criteria called RECIST v1.1.
The cancer has only spread to the brain in certain areas, but not to the brain stem or other critical parts of the brain.

BELIEVE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from time of first dose until death from any cause, assessed up to approximately 48 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from time of first dose until death from any cause, assessed up to approximately 48 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
6- month Progression Free Survival (PFS) rate
Secondary outcome measures
Incidence of adverse events
Objective Response Rate
Overall Survival (OS)
+1 more
Other outcome measures
Tissue and blood based biomarkers

Side effects data

From 2015 Phase 4 trial • 45 Patients • NCT02036424
vitreous hemorrhage
worsening of cataract
posterior capsule opacification
vitreous syneresis
cranial nerve VI palsy
colon cancer
Study treatment Arm

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

BELIEVE Trial Design

1Treatment groups
Experimental Treatment
Group I: Experimental TreatmentExperimental Treatment1 Intervention
Induction (ABCE): Atezolizumab 1200 mg, Bevacizumab 15 mg/kg, Carboplatin AUC5, Etoposide 100 mg/m2, given IV Q3weeks Maintenance (AB): Atezolizumab 1200 mg and Bevacizumab 15 mg/kg given IV Q3weeks for 1 year, or until disease progression, or unacceptable toxicity
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4

Find a Location

Who is running the clinical trial?

University of MichiganOTHER
1,744 Previous Clinical Trials
6,585,020 Total Patients Enrolled
Kamya SankarLead Sponsor
Genentech, Inc.Industry Sponsor
1,531 Previous Clinical Trials
566,728 Total Patients Enrolled

Media Library

Bevacizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05588388 — Phase 2
Small Cell Lung Cancer Research Study Groups: Experimental Treatment
Small Cell Lung Cancer Clinical Trial 2023: Bevacizumab Highlights & Side Effects. Trial Name: NCT05588388 — Phase 2
Bevacizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05588388 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any positions open for patients in this study?

"No, this particular study is not presently looking for participants. The clinicaltrials.gov website indicates that the study was first posted on February 1st 2023 and last updated on October 18th 2022. There are 2377 other trials active recruiting patients at the moment though."

Answered by AI

Has the FDA sanctioned this experimental procedure?

"There is some data supporting the safety of this experimental treatment, but none yet for efficacy. We gave it a score of 2."

Answered by AI
~26 spots leftby Jun 2026